WVE vs. CRSP, ABVX, MRUS, TGTX, VKTX, ACAD, CYTK, ADMA, AKRO, and ACLX
Should you be buying WAVE Life Sciences stock or one of its competitors? The main competitors of WAVE Life Sciences include CRISPR Therapeutics (CRSP), Abivax (ABVX), Merus (MRUS), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Cytokinetics (CYTK), ADMA Biologics (ADMA), Akero Therapeutics (AKRO), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry.
WAVE Life Sciences vs. Its Competitors
CRISPR Therapeutics (NASDAQ:CRSP) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.
In the previous week, CRISPR Therapeutics had 23 more articles in the media than WAVE Life Sciences. MarketBeat recorded 29 mentions for CRISPR Therapeutics and 6 mentions for WAVE Life Sciences. CRISPR Therapeutics' average media sentiment score of 0.69 beat WAVE Life Sciences' score of 0.68 indicating that CRISPR Therapeutics is being referred to more favorably in the media.
WAVE Life Sciences has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat WAVE Life Sciences' return on equity.
CRISPR Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of -0.95, meaning that its stock price is 195% less volatile than the S&P 500.
69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 24.0% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
WAVE Life Sciences has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.
CRISPR Therapeutics currently has a consensus target price of $71.60, indicating a potential upside of 19.89%. WAVE Life Sciences has a consensus target price of $20.27, indicating a potential upside of 124.06%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than CRISPR Therapeutics.
Summary
WAVE Life Sciences beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.
Get WAVE Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
WAVE Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:WVE) was last updated on 8/15/2025 by MarketBeat.com Staff
MarketBeat All Access